Alan-Michael Vargas
Family Medicine · Parachute, CONPI 1619283991
Payments from drug & device makers
Across 372 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$722
- GSK$465
- Amgen$419
- Lilly USA, LLC$369
- Pfizer$335
- plus $3K from 35 others
What the payments were for
- Food & beverage$6,62199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$102
How this compares
$6,667 in reported general payments places this provider in the 95th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $91,079 |
| EliquisApixaban | 84 | $82,667 |
| JardianceEmpagliflozin | 56 | $79,451 |
| Xeljanz XrTofacitinib Citrate | 13 | $76,479 |
| RexultiBrexpiprazole | 40 | $73,599 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $72,120 |
| MounjaroTirzepatide | 45 | $63,870 |
| FarxigaDapagliflozin Propanediol | 49 | $52,529 |
| TrulicityDulaglutide | 32 | $40,520 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $34,636 |
| MyrbetriqMirabegron | 42 | $26,786 |
| LinzessLinaclotide | 44 | $23,512 |
| JanuviaSitagliptin Phosphate | 17 | $23,440 |
| XareltoRivaroxaban | 19 | $21,766 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $18,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $369 | $104,39077 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $465 | $90,443109 claims |
| PfizerEliquis | $335 | $82,66784 claims |
| Boehringer IngelheimJardiance | $145 | $79,45156 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $226 | $73,59940 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $722 | $66,59962 claims |
| MerckJanuvia, Belsomra | $38 | $38,04043 claims |
| Astellas Pharma US IncMyrbetriq | $264 | $26,78642 claims |
| AbbVieLinzess | $1,410 | $23,51244 claims |
| Johnson & JohnsonXarelto | $256 | $21,76619 claims |
| NovartisEntresto | $19 | $16,77811 claims |
| Novo NordiskOzempic | $222 | $13,52414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Parachute
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
- Astrid LampeyFraser$568K
- Kari UusinarkausWoodland Park$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.